Tamara Pinkhasova, MD
Internal Medicine · Bronx, NYNPI 1306888490
Payments from drug & device makers
Across 279 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$858
- AbbVie$699
- GSK$649
- Bayer$334
- Lilly USA, LLC$312
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,75499%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $1,093 |
| AstraZeneca | 42 | $858 |
| AbbVie(2 entities) | 37 | $699 |
| GSK | 27 | $649 |
| Bayer | 17 | $334 |
| Lilly USA, LLC | 14 | $312 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $288 |
| Pfizer | 13 | $274 |
| Novartis | 9 | $179 |
| Merck | 9 | $158 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $139 |
| Astellas Pharma US Inc | 4 | $111 |
| Gilead | 5 | $92 |
| Amgen | 5 | $90 |
| Dexcom, Inc. | 3 | $60 |
| Amarin Pharma, Inc. | 3 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Johnson & Johnson | 1 | $28 |
| Ardelyx, Inc. | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,814 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 197 | $197,271 |
| FarxigaDapagliflozin Propanediol | 165 | $131,088 |
| TrulicityDulaglutide | 82 | $98,287 |
| JanumetSitagliptin Phos/Metformin Hcl | 97 | $96,724 |
| OzempicSemaglutide | 86 | $87,473 |
| EliquisApixaban | 84 | $71,514 |
| JanuviaSitagliptin Phosphate | 54 | $53,490 |
| LinzessLinaclotide | 87 | $45,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $44,432 |
| EntrestoSacubitril/Valsartan | 50 | $43,261 |
| Metformin Hcl | 487 | $41,205 |
| TradjentaLinagliptin | 46 | $39,129 |
| KerendiaFinerenone | 49 | $39,123 |
| MounjaroTirzepatide | 27 | $29,117 |
| Nurtec OdtRimegepant Sulfate | 17 | $28,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $20 | $236,400243 claims |
| MerckJanumet, Januvia, Janumet Xr | $158 | $171,363183 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $858 | $148,765207 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $312 | $127,404109 claims |
| PfizerEliquis, Nurtec Odt | $274 | $100,437101 claims |
| Novo NordiskOzempic, Rybelsus | $1,093 | $99,99898 claims |
| AbbVieLinzess, Restasis, Creon | $699 | $64,457112 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $649 | $50,54079 claims |
| NovartisEntresto | $179 | $43,26150 claims |
| BayerKerendia | $334 | $39,12349 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $14,47927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.